Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

CRISPR01:59

CRISPR

57.4K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
57.4K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

1.6K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
1.6K
What is Genetic Engineering?00:49

What is Genetic Engineering?

79.6K
Overview
79.6K
Homologous Recombination02:31

Homologous Recombination

62.5K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
62.5K
CRISPR and crRNAs02:53

CRISPR and crRNAs

18.7K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
18.7K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

6.6K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Hemophilia Gene Therapy: The End of the Beginning?

Human gene therapy·2023
Same author

Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.

Blood·2021
Same author

Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants.

Nature communications·2020
查看所有相关文章

相关实验视频

Updated: Jan 12, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.3K

针对出血障碍的CRISPR和基因编辑技术.

Thierry VandenDriessche1, Mathias Janssens2, Marinee K Chuah3

  • 1Department of Gene Therapy and Regenerative Medicine, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Building D, room JD.3.56, Laarbeeklaan 103, Brussels B-1090, Belgium.

Therapeutic advances in hematology
|November 3, 2025
PubMed
概括

基因编辑为治疗血友病A和B提供了一个有希望的新途径,超越目前的基因疗法. 临床前研究表明持续的因子生产,为临床试验铺平了道路.

关键词:
克里斯普尔是什么意思?克里斯普尔是什么意思?这就是TALEN.ZFNN 在线播放腺相关的腺相关的基础编辑 基础编辑第九因子XIX因子第八个因子的因素.血友病 (hemophilia) 是一种血友病.纳米颗粒是一种纳米粒子.

更多相关视频

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.9K
Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
08:27

Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Published on: April 10, 2018

14.1K

相关实验视频

Last Updated: Jan 12, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.3K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.9K
Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
08:27

Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Published on: April 10, 2018

14.1K

科学领域:

  • 生物技术是生物技术.
  • 血液学 血液学 血液学
  • 基因工程是一种基因工程.

背景情况:

  • 最近批准用于治疗血友病A和B的基因疗法标志着一个重要的进步.
  • 现有疗法需要提高疗效,安全性和表达稳定性,特别是对于儿科患者.
  • 基因编辑为解决传统基因疗法的局限性提供了一种新的策略.

研究的目的:

  • 探索基因编辑技术治疗血友病A和B的潜力.
  • 在临床前模型中评估基因编辑策略的有效性和安全性.
  • 评估基因编辑对持续的VIII或IX因子生产的可行性.

主要方法:

  • 利用指核酶,大核酶,TALEN和CRISPR技术进行向DNA修饰.
  • 研究了用于DSB独立基因编辑的CRISPR衍生基因和主要编辑器.
  • 在患者衍生细胞和血友病A或B小鼠模型中进行了临床前研究.

主要成果:

  • 在临床前模型中,基因编辑证明了持续的有效性和XVIII或IX因子的产生.
  • 下一代编辑器 (基础/主要) 提供了无需DSB的更安全的基因改造的潜力.
  • 临床前数据支持基因编辑向严重血友病的临床试验的进步.

结论:

  • 基因编辑对血友病的未来治疗具有重大前景.
  • 进一步的研究对于解决非目标效应,免疫反应和传递挑战至关重要.
  • 将基因编辑成功转移到诊所可能会彻底改变血友病护理.